Liposit Prolib (Fluvastatin Sodium)

Fluvastatin sodium is indicated for disorders of lipid metabolism and for reducing cardiovascular risk.

• Hypercholesterolemia: lowers total and LDL cholesterol to target levels.
• Primary prevention of cardiovascular disease: reduces the incidence of myocardial infarction and stroke in at‑risk patients.
• Familial hypercholesterolemia: helps achieve cholesterol goals in genetically predisposed individuals.

• Fluvastatin sodium competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis. This inhibition reduces intracellular cholesterol, leading to up‑regulation of LDL receptors on hepatocyte surfaces and increased clearance of circulating LDL‑cholesterol, thereby lowering plasma lipid concentrations.

Fluvastatin sodium may cause a range of adverse reactions.

Common Side Effects

• Headache: mild to moderate intensity.
• Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.
• Myalgia: muscle aches without weakness.
• Elevated liver enzymes: transient increases in ALT/AST.
• Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with risk of renal failure.
• Acute liver injury: marked elevation of hepatic enzymes or hepatitis.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Myopathy with weakness: muscle pain accompanied by reduced strength.
• Stevens‑Johnson syndrome: rare severe skin reaction.

When prescribing fluvastatin sodium, clinicians should consider several safety measures.

• Liver function monitoring: assess baseline and periodic ALT/AST levels.
• Renal function assessment: adjust use in patients with impaired clearance.
• Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors.
• Pregnancy and lactation: use only if potential benefit justifies risk.
• Active liver disease: contraindicated in patients with ongoing hepatic pathology.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Fluvastatin sodium interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may raise fluvastatin levels.
• Gemfibrozil: increases risk of myopathy and rhabdomyolysis.
• Cyclosporine: potentiates statin‑related muscle toxicity.
• High‑dose niacin: augments muscle adverse events.
• Certain antivirals (e.g., protease inhibitors): elevate statin exposure.

Moderate Interactions (Monitor Closely)

• Amiodarone: may modestly increase statin concentrations.
• Digoxin: monitor for potential increased serum levels.
• Warfarin: observe INR for possible enhancement of anticoagulant effect.
• Beta‑blockers: watch for additive hypotensive effects.
• Antihypertensives: may require blood pressure monitoring.